Welcome to our dedicated page for Sono Tek SEC filings (Ticker: SOTK), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Ultrasonic coating may sound simple, yet Sono-Tek’s SEC filings can stretch past 250 pages of dense engineering jargon and revenue breakouts. Finding where the company discloses semiconductor backlog or which executive just sold shares is time-consuming.
Stock Titan solves that pain. Our AI reads every Sono-Tek annual report 10-K simplified, every Sono-Tek quarterly earnings report 10-Q filing, and each Sono-Tek 8-K material events explained, then delivers plain-English summaries, key metrics, and red-flag alerts. Want immediate visibility into Sono-Tek insider trading Form 4 transactions? We stream Sono-Tek Form 4 insider transactions real-time so you can monitor executive stock moves before the market reacts.
Use our platform to:
- Compare R&D spending on new hydrogen-fuel coatings across successive 10-Qs.
- Track Sono-Tek proxy statement executive compensation to evaluate management incentives.
- Spot segment revenue shifts in medical device coatings without wading through footnotes.
- Receive AI-driven alerts when a fresh contract is disclosed in an 8-K.
From “understanding Sono-Tek SEC documents with AI” to detailed Sono-Tek earnings report filing analysis, Stock Titan keeps every filing type in one place—updated the moment EDGAR releases it and decoded so you can act with confidence.
Sono-Tek (SOTK) reported Q2 FY26 results with net sales of $5,163,000 and diluted EPS of $0.03. Gross profit was $2,590,000 with a 50.2% gross margin. Operating income rose to $421,000, a 47% increase year over year as higher-margin mix and lower operating expenses helped results.
Medical sales grew 150% on balloon coating shipments, while Alternative/Clean Energy was steady and Electronics/Microelectronics held near prior-year levels. APAC revenue increased 153% driven by medical and energy orders, partially offsetting a 22% decline in the U.S. and Canada. Backlog was $11,210,000 at August 31, 2025, up 50% sequentially from Q1.
For the first half, sales were $10,296,000 and operating income $905,000 (up 73%). Cash, cash equivalents and marketable securities totaled $10,568,000 with no outstanding debt. Operating cash flow was $(1,099,000), reflecting higher accounts receivable tied to revised timing on a $4.4 million multi-unit order.
Sono-Tek Corporation reported via an 8-K that it issued a press release announcing an order for medical device coating systems valued at $2.8 million.
The disclosure was furnished under Item 2.02 (Results of Operations and Financial Condition) and Item 7.01 (Regulation FD Disclosure) and includes Exhibit 99.1, a press release dated October 13, 2025. The furnished information is not deemed filed under Section 18 of the Exchange Act.
Sono-Tek Corporation filed an 8-K announcing that it issued a press release with financial results for the quarter ended August 31, 2025. The release is furnished as Exhibit 99.1 and relates to Items 2.02 (Results of Operations and Financial Condition) and 7.01 (Regulation FD).
The company states the information furnished under Item 7.01, including Exhibit 99.1, is not deemed “filed” under Section 18 of the Exchange Act and is not incorporated by reference into other filings. The press release is dated October 14, 2025.
Sono-Tek Corporation shareholders elected four director nominees to serve until the 2026 annual meeting and ratified the appointment of CBIZ CPAs P.C. as independent auditors for the fiscal year ending February 28, 2026. Shareholders also approved, in a non-binding advisory vote, the compensation of the company’s named executive officers and recommended a three-year frequency for future non-binding shareholder votes on executive compensation, which the company accepted.
Lawal Adeniyi, a director of Sono-Tek Corporation (SOTK), reported an options acquisition on Form 4 dated 08/21/2025. The filing shows purchase of 7,018 Sono-Tek options with an exercise price of $3.25, exercisable beginning 08/21/2026 and expiring 08/21/2035, representing 7,018 underlying common shares. After the transaction the reporting person beneficially owns 12,351 shares directly. The Form 4 was filed by one reporting person.
Eric Haskell, a director of Sono-Tek Corporation (SOTK), reported acquiring 7,018 stock options on 08/21/2025 at an exercise price of $3.25 per share. The options become exercisable on 08/21/2026 and expire on 08/21/2035, and they cover 7,018 shares of common stock. Following the reported transaction, Mr. Haskell directly beneficially owns 35,377 shares.
Joseph Riemer, a director of Sono-Tek Corporation (SOTK), reported acquiring 7,018 shares on 08/21/2025 through the exercise of Sono-Tek stock options with an exercise price of $3.25 per share. The options are exercisable beginning 08/21/2026 and expire 08/21/2035. Following the reported transaction, Mr. Riemer beneficially owns 27,377 shares of common stock. The Form 4 was signed on 08/22/2025.
Carol O'Donnell, a director of Sono-Tek Corporation (SOTK), reported acquiring derivative securities on 08/21/2025. The filing shows acquisition of 7,018 Sono-Tek options with a $3.25 exercise price, exercisable beginning 08/21/2026 and expiring 08/21/2035. After the reported transaction, Ms. O'Donnell directly beneficially owned 25,377 shares of common stock. The Form 4 was signed 08/22/2025.
Sono-Tek director Kirk M. Warshaw reported exercising stock options on 08/21/2025, acquiring 7,018 shares of Sono-Tek Corp (SOTK) at an exercise price of $3.25 per share. Following the transaction the reporting person beneficially owns 7,018 shares directly. The Form 4 was signed on 08/22/2025.
FAQ
What is the current stock price of Sono Tek (SOTK)?
What is the market cap of Sono Tek (SOTK)?
